CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
Imatinib (Glivec)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00122473
NCT00122473Phase 2Completed
CompareCT.gov

Open-label Trial of Glivec® (Imatinib Mesylate) in Patients With Primary or Recurrent Dermatofibrosarcoma Protuberans

Dermatologic Cooperative Oncology Group·interventional·Posted Jul 22, 2005·Updated Jul 29, 2011

In Brief

A Phase 2 clinical trial evaluating Imatinib (Glivec) for Dermatofibrosarcoma. Completed, across 4 sites.

Detailed Summary

The purpose of this study is to determine whether imatinib is effective in the treatment of primary and recurrent dermatofibrosarcoma protuberans (DFSP).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDermatofibrosarcoma
CountriesGermany
Collaborators--

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 22, 2005
Enrollment StartJan 1, 2004
Study CompletionJan 1, 2007
TodayJul 2, 2026
Posted 20.9 years ago

Interventions

Imatinib (Glivec)drug